HomeREGULATORY
REGULATORY

“Huge Seller” Re-Pricing to Hit Sovaldi, Harvoni, Avastin, Plavix
(Jan.20.2016)

A total of six products of four brands - Sovaldi (sofosbuvir), Harvoni (ledipasvir + sofosbuvir), Avastin (bevacizumab), and Plavix (clopidogrel) - will face a new special re-pricing rule to be rolled out in April for drugs generating “huge sales.”

The plan was reported by the Ministry of Health, Labor and Welfare (MHLW) at a general meeting of the Central Social Insurance Medical Council (Chuikyo) on January 20.
(LOG IN FOR FULL STORY)